To determine the physiological roles of peroxisome proliferator-activated receptor  (PPAR), null mice were constructed by targeted disruption of the ligand binding domain of the murine PPAR gene. Homozygous PPAR-null term fetuses were smaller than controls, and this phenotype persisted postnatally. Gonadal adipose stores were smaller, and constitutive mRNA levels of CD36 were higher, in PPAR-null mice than in controls. In the brain, myelination of the corpus callosum was altered in PPAR-null mice. PPAR was not required for induction of mRNAs involved in epidermal differentiation induced by O-tetradecanoylphorbol-13-acetate (TPA). The hyperplastic response observed in the epidermis after TPA application was significantly greater in the PPAR-null mice than in controls. Inflammation induced by TPA in the skin was lower in wild-type mice fed sulindac than in similarly treated PPAR-null mice. These results are the first to provide in vivo evidence of significant roles for PPAR in development, myelination of the corpus callosum, lipid metabolism, and epidermal cell proliferation.
Uncoupling protein-3 (UCP3) is a mitochondrial protein that can diminish the mitochondrial membrane potential. Levels of muscle Ucp3 mRNA are increased by thyroid hormone and fasting. Ucp3 has been proposed to influence metabolic efficiency and is a candidate obesity gene. We have produced a Ucp3 knockout mouse to test these hypotheses. The Ucp3 (؊/؊) mice had no detectable immunoreactive UCP3 by Western blotting. In mitochondria from the knockout mice, proton leak was greatly reduced in muscle, minimally reduced in brown fat, and not reduced at all in liver. These data suggest that UCP3 accounts for much of the proton leak in skeletal muscle. Despite the lack of UCP3, no consistent phenotypic abnormality was observed. The knockout mice were not obese and had normal serum insulin, triglyceride, and leptin levels, with a tendency toward reduced free fatty acids and glucose. Knockout mice showed a normal circadian rhythm in body temperature and motor activity and had normal body temperature responses to fasting, stress, thyroid hormone, and cold exposure. The base-line metabolic rate and respiratory exchange ratio were the same in knockout and control mice, as were the effects of fasting, a 3-adrenergic agonist (CL316243), and thyroid hormone on these parameters. The phenotype of Ucp1/Ucp3 double knockout mice was indistinguishable from Ucp1 single knockout mice. These data suggest that Ucp3 is not a major determinant of metabolic rate but, rather, has other functions.Human obesity is the result of energy intake greater than metabolic expenditure and is increasing in incidence (1). On an evolutionary time scale, obesity is a recent development, attributed to the interaction of predisposing genetic backgrounds with a sedentary lifestyle and an abundance of food (2, 3). Little is known about the molecular mechanisms and genes that contribute to the regulation of metabolic rate. For example, metabolic efficiency decreases with increased food intake, and it increases with lowered food intake (4), but the mechanistic details are unknown.The discovery of uncoupling protein (UCP, 1 now named UCP1) illustrated one way to regulate metabolic efficiency. UCP1 uncouples oxidative phosphorylation by allowing leakage of protons into the mitochondrial matrix without the phosphorylation of ADP (5). Heat is released because UCP1 degrades the proton gradient energy without storing it chemically or using it to perform physical work. At the whole-body level, this shows up as metabolic inefficiency. Ucp1 is expressed only in brown adipose tissue (BAT), which is a major heat-producing tissue in small mammals. In addition to cold-induced thermogenesis, BAT and UCP1 have been implicated in diet-induced thermogenesis, the increased energy expenditure that accompanies increased food intake (6). Activation of BAT and increased expression of Ucp1 cause reduced adiposity (7-9). However, BAT is present in only small amounts in large mammals, so its role in regulating energy homeostasis in adult humans is problematic (10).Interest in UCPs incr...
Insulin inhibits glucose production through both direct and indirect effects on the liver; however, considerable controversy exists regarding the relative importance of these effects. The first aim of this study was to determine which of these processes dominates the acute control of hepatic glucose production (HGP). Somatostatin and portal vein infusions of insulin and glucagon were used to clamp the pancreatic hormones at basal levels in the nondiabetic dog. After a basal sampling period, insulin infusion was switched from the portal vein to a peripheral vein. As a result, the arterial insulin level doubled and the hepatic sinusoidal insulin level was reduced by half. While the arterial plasma FFA level and net hepatic FFA uptake fell by 40-50%, net hepatic glucose output increased more than 2-fold and remained elevated compared with that in the control group. The second aim of this study was to determine the effect of a 4-fold rise in head insulin on HGP during peripheral hyperinsulinemia and hepatic insulin deficiency. Sensitivity of the liver was not enhanced by increased insulin delivery to the head. Thus, this study demonstrates that the direct effects of insulin dominate the acute regulation of HGP in the normal dog. IntroductionHepatic glucose production (HGP) accounts for the majority of whole-body glucose production and is tightly regulated by insulin in the healthy individual. Since hepatic insulin resistance in diabetic patients results in excess HGP and fasting hyperglycemia (1), it is critical to understand the mechanisms by which insulin regulates this process. Insulin reduces HGP by acting both directly and indirectly on the liver (2); however, there is considerable controversy regarding the relative importance of insulin's direct versus indirect effects under physiological conditions. Insulin acts directly by binding to hepatic insulin receptors and thereby activating insulin signaling pathways in the liver. These effects have been demonstrated in various models. In isolated rat hepatocytes, insulin inhibits glucose production through inhibition of gluconeogenesis (3) and glycogenolysis (4). In the dog, an acute selective increase (5) or decrease (6) in hepatic insulin level (so that the arterial insulin level was kept constant) resulted in very rapid suppression or stimulation, respectively, of HGP. In addition, liver-specific insulin receptor knockout (LIRKO) mice, which lack hepatic insulin receptors from birth, demonstrate severe hepatic insulin resistance (7). These studies, and others, demonstrate that insulin acts directly on the liver to regulate HGP.Insulin's indirect effects include reduction of glucagon secretion at the pancreas (8), inhibition of lipolysis in fat (which reduces circulating lipids and glycerol availability for gluconeogenesis) (9), and decreased protein catabolism in muscle (which further reduces gluconeogenic precursor availability) (10), and in addition, recent studies in the mouse and rat suggest that hypothalamic insulin signaling may also play an important role ...
The mitochondrial glycerol phosphate dehydrogenase (mGPD) is important for metabolism of glycerol phosphate for gluconeogenesis or energy production and has been implicated in thermogenesis induced by cold and thyroid hormone treatment. mGPD in combination with the cytosolic glycerol phosphate dehydrogenase (cGPD) is proposed to form the glycerol phosphate shuttle, catalyzing the interconversion of dihydroxyacetone phosphate and glycerol phosphate with net oxidation of cytosolic NADH. We made a targeted deletion in Gdm1 and produced mice lacking mGPD. On a C57BL/6J background these mice showed a 50% reduction in viability compared with wild-type littermates. Uncoupling protein-1 mRNA levels in brown adipose tissue did not differ between mGPD knockout and control pups, suggesting normal thermogenesis. Pups lacking mGPD had decreased liver ATP and slightly increased liver glycerol phosphate. In contrast, liver and muscle metabolites were normal in adult animals. Adult mGPD knockout animals had a normal cold tolerance, normal circadian rhythm in body temperature, and demonstrated a normal temperature increase in response to thyroid hormone. However, they were found to have a lower body mass index, a 40% reduction in the weight of white adipose tissue, and a slightly lower fasting blood glucose than controls. The phenotype may be secondary to consequences of the obligatory production of cytosolic NADH from glycerol metabolism in the mGPD knockout animal. We conclude that, although mGPD is not essential for thyroid thermogenesis, variations in its function affect viability and adiposity in mice.The glycerol phosphate shuttle, composed of the FAD-dependent mitochondrial glycerol phosphate dehydrogenase (mGPD, 1 EC 1.1.99.5) and the NAD(H)-dependent cytosolic glycerol phosphate dehydrogenase (cGPD, EC 1.1.1.8), is generally considered to play a role in the oxidation of cytosolic NADH formed during glycolysis. In mice the mitochondrial enzyme is encoded by a single gene, Gdm1, on chromosome 2 (1). The cytosolic enzyme has both an adult form, encoded by Gdc1 on chromosome 15 (2) and an embryonic form, encoded by Gdc2 on chromosome 9 (3). The embryonic form has not been found in liver or kidney during gestation but persists in brain for several weeks following birth (4) and in the epididymal white adipose tissue until at least 5 days of age (5). It has recently been reported that mice lacking the adult form of cGPD have elevated dihydroxyacetone phosphate and decreased glycerol phosphate and ATP levels in muscle following exercise (6), although these mice otherwise appear normal, having normal weights and litter sizes (7). Surprisingly, these cGPD-deficient mice grow normally even on a diet essentially free of glycerol (6), presumably by using the dihydroxyacetone phosphate acyl transferase pathway for lipid synthesis. The findings suggest that a lack of cGPD alters the cellular redox status in muscle, whereas pancreatic islet function is relatively normal and liver is only mildly affected, confirming the ability of alter...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.